ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
Sendero Resources Corporation (PK)

Sendero Resources Corporation (PK) (SRRCF)

0.20
0.00
(0.00%)
마감 08 12월 6:00AM

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

SRRCF 뉴스

공식 뉴스 전용
0개의 기사가 발견되었습니다.
europa7 europa7 5 분 전
Citi, JP Morgan, others complete tokenization settlement trials
December 5, 2024
https://www.ledgerinsights.com/citi-wells-fargo-others-complete-tokenization-settlement-trials/

https://www.sifma.org/wp-content/uploads/2024/12/RSN-Technical-Report-FINAL.pdf

HBARUSD
tedpeele tedpeele 5 분 전
Moronic. The stock immediately went crazy Marco. Did you somehow miss that? That wasn’t because people said “oh look we are now in a commercialization process now that we’re in foundries that will make take years.

You’re looking back with 2020, but it does not mirror or reflect the me
LWLG
learningcurve2020 learningcurve2020 5 분 전
All of it is what happens when you have a therapy that shows maybe just a touch of efficacy but is far too expensive to commercialize.  Handsomely paid management  takes twenty years for a disease that kills almost all in under two years.  Runs multiple combo's trials in hopes something positive occ
NWBO
dalesio_98 dalesio_98 6 분 전
If I am not mistaken, Eno had options and not shares, they were out of the money.

Good luck to All!

I am not the only person who believes this occurred because of the ridiculously low upfront purchase price, noting that, last I looked, Eno still has his shares.
Resqnine Resqnine 8 분 전
Looking good, hopefully slow moves upwards 
EOSE
rocioyogi rocioyogi 8 분 전
I’m totally on the same page as you, but I’m thinking closer to .85 but would be so happy with a dollar now; doesn’t matter we’re sitting pretty just a matter of short short time
ELTP
rogers711 rogers711 8 분 전
But again it's all my opinion, if you want to call it unsubstantiated you aren't wrong but logically it's more accurate than this month like many are claiming...
RDGL
rogers711 rogers711 10 분 전
Agreed... I guess that was my point in my opinion is looking logically at the timeline and not running trials parallel to eachother it's going to take a bit longer than others feel it will...
RDGL
Jahvik Jahvik 10 분 전
I'm amazed at how much money I made!!
Well...I guess I was smart enough to buy in trips over and over and over and over and over

I only sold 50 million too lol
HMBL
StayHumble StayHumble 10 분 전
Xperts Must be💹 JUMBO SHORT💹 $SHMP $10 💹Markets Primed!
SHMP
rogers711 rogers711 11 분 전
It was just my opinion, but think logically, they haven't started trials yet in Southeast Asia or even announced a timeline and those will take months in my opinion... 
RDGL
KIPK KIPK 13 분 전
Had been floating on dualities of $0.0002 to $0.05-0.1.................
Outcome is reflection of efforts and creativity................
Years of innovations & crawling..... leading to fortition of efforts and flying......... imo
SRMX
rosemountbomber rosemountbomber 13 분 전
And who knows if after 10 years they still don't get it right.
AMRN
02opida 02opida 15 분 전
WASHINGTON—President-elect Donald Trump’s transition team is drafting several versions of his long-promised executive order to curtail automatic citizenship for anyone born in the U.S., according to people familiar with the matter, as his aides prepare for an expanded legal fight.

Tru
JOoa0ky JOoa0ky 17 분 전
Incorrect. $3.50 wall holds.
FNMA
02opida 02opida 17 분 전
Trump Prepares for Legal Fight Over His ‘Birthright Citizenship’ Curbs
02opida 02opida 19 분 전
OPEC+ extends its production cuts. MEG Energy wins a nod of approval from Fitch Ratings, while Kiwetinohk Energy has its eye on Alberta's data centre dreams. Kolibri Global cheers on its wells in Oklahoma, and LNG Energy puts itself up for sale
02opida 02opida 19 분 전
HII - HII Christens Virginia-Class Attack Submarine Arkansas (SSN 800)
HII
02opida 02opida 19 분 전
SNDX - Syndax Presents Positive Revuforj(TM) (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
SNDX
Humbert Humbert 20 분 전
Should skyrocket shortly
BNCM
02opida 02opida 20 분 전
ADPT - Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ(TM) and Its Impact on Blood Cancer Treatment Decisions
closetokathy closetokathy 21 분 전
What exactly is Kate trying to accomplish? Does anyone know? I wish her luck as I have my eyes set on a Toyota Prius.
CEOS
hnbadger1 hnbadger1 23 분 전
http://cslide.ctimeetingtech.com/a

SAVXL wow, now famous Prof Timo Grimmer,
¡Technical University Munich, involved in the study, is presenting in Vienna, April AD/PD:
PHASE IIB/III ATTENTION-AD STUDY: OVER THREE YEARS OF CONTINUOUS TREATMENT WITH ORAL BLARCAMESINE CONTIN
AVXL

최근 히스토리

Delayed Upgrade Clock